2-Hydroxypropyl-beta-cyclodextrin: Clinical Trials

5 trials of 2-Hydroxypropyl-beta-cyclodextrin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 1 completed, 1 unknown. 5 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Terminated 3, Completed 1, Unknown 1
Phase 23Terminated 2, Completed 1

Follow 2-Hydroxypropyl-beta-cyclodextrin: new trials by email Literature Review of 2-Hydroxypropyl-beta-cyclodextrin trials Research Report on 2-Hydroxypropyl-beta-cyclodextrin

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1
Hydroxypropyl-beta-cyclodextrin, Placebo - Niemann-Pick Disease, Type C1
Phase 3UnknownCyclo Therapeutics, Inc.942021-07-202024-06-04
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
VTS-270 - Niemann-Pick Disease, Type C
Phase 2 / Phase 3TerminatedMandos LLC22019-12-022023-12-26
Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System
Adrabetadex - Niemann-Pick Type C Disease
Phase 3TerminatedMandos LLC272018-06-182024-01-17
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Adrabetadex - Niemann-Pick Disease, Type C
Phase 2 / Phase 3TerminatedMandos LLC662015-12-232023-08-29
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C
Phase 2 / Phase 3CompletedMandos LLC562015-10-012023-02-22

Conditions studied

Niemann-Pick Disease, Type C (5)  ·  Cognitive Dysfunction (2)  ·  Deglutition Disorders (2)  ·  Disease (2)  ·  Mobility Limitation (2)

Sponsors

Mandos LLC (4)  ·  Cyclo Therapeutics, Inc. (1)

Countries

United States (4)  ·  Australia (3)  ·  Germany (3)  ·  Turkey (Türkiye) (3)  ·  United Kingdom (3)  ·  France (2)  ·  New Zealand (2)  ·  Singapore (2)  ·  Spain (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Costa Rica (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)

Top investigators

Karen Mullen, MD (1)

Results publications

PMID 36279795, PMID 40525490

NIH funding

2015 (2)